title: Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.
abstract: OBJECTIVE
  The Androgen Excess Society (AES) charged a task force to review all available data and recommend an evidence-based definition for polycystic ovary syndrome (PCOS), whether already in use or not, to guide clinical diagnosis and future research.
  
  
  METHODS
  Participants included expert investigators in the field.
  
  
  METHODS
  Based on a systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, we tried to identify studies evaluating the epidemiology or phenotypic aspects of PCOS.
  
  
  METHODS
  The task force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by the AES Board of Directors. No section was finalized until all members were satisfied with the contents and minority opinions noted. Statements that were not supported by peer-reviewed evidence were not included.
  
  
  CONCLUSIONS
  Based on the available data, it is the view of the AES Task Force on the Phenotype of PCOS that there should be acceptance of the original 1990 National Institutes of Health criteria with some modifications, taking into consideration the concerns expressed in the proceedings of the 2003 Rotterdam conference. A principal conclusion was that PCOS should be first considered a disorder of androgen excess or hyperandrogenism, although a minority considered the possibility that there may be forms of PCOS without overt evidence of hyperandrogenism but recognized that more data are required before validating this supposition. Finally, the task force recognized, and fully expects, that the definition of this syndrome will evolve over time to incorporate new research findings.
authors.affiliation: Cedars-Sinai Medical Center and The David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Azziz
authors.forename: Enrico
authors.initials: E
authors.lastname: Carmina
authors.forename: Didier
authors.initials: D
authors.lastname: Dewailly
authors.forename: Evanthia
authors.initials: E
authors.lastname: Diamanti-Kandarakis
authors.forename: Hector F
authors.initials: HF
authors.lastname: Escobar-Morreale
authors.forename: Walter
authors.initials: W
authors.lastname: Futterweit
authors.forename: Onno E
authors.initials: OE
authors.lastname: Janssen
authors.forename: Richard S
authors.initials: RS
authors.lastname: Legro
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Norman
authors.forename: Ann E
authors.initials: AE
authors.lastname: Taylor
authors.forename: Selma F
authors.initials: SF
authors.lastname: Witchel
mesh_terms: D000728:Androgens / Q000378:metabolism; D032921:Consensus; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000175:diagnosis*; D011085:Polycystic Ovary Syndrome / Q000145:classification / Q000175:diagnosis*; D012955:Societies, Medical
chemical_list: D000728:Androgens